In a report released today, Ami Fadia from Needham maintained a Buy rating on Alkermes, with a price target of $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given his Buy rating due to a combination of factors that highlight Alkermes’ strong financial performance and potential for future growth. The company reported impressive second-quarter earnings for 2025, with an EPS of $0.52, significantly surpassing the consensus estimate of $0.24. This was largely attributed to higher-than-expected revenues, particularly from their key products such as Vivtrol, Aristada, and Lybalvi, which all exceeded sales expectations due to favorable Medicaid utilization adjustments.
Additionally, Alkermes’ management has maintained their financial guidance for 2025, which suggests confidence in their ongoing business strategy. While the immediate stock movement may not be substantial due to the alignment of sales with consensus expectations, the upcoming detailed Phase 2b data for ALKS-2680 and NT2 data are anticipated to be pivotal for investors. These elements collectively support the Buy rating as they indicate both current financial strength and promising future developments.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $42.00 price target.